Edgewise Therapeutics reported the appointment of Behrad Derakhshan, Ph.D., to the newly created position of Chief Business Officer. Dr. Derakhshan brings over 10 years of experience from rare/ultra-rare disease companies with expertise in executing strong business partnerships, capital formation and corporate and business development strategy. This comes at an important time as Edgewise advances EDG-5506, the company's lead product candidate, in clinical development for Duchenne and Becker muscular dystrophy (DMD and BMD). Dr. Derakhshan joins Edgewise from VectivBio.